Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations

Table 4 Univariate analysis table of factors affecting change in hepatic steatosis

Characteristic	n	Beta	95%CI	P value
Testosterone	381	-0.66	-1.0, -0.37	< 0.001
Age (yr)	38	-0.03	-0.05, 0.00	0.075
BMI (kg/m2)	38	0.06	0.02, 0.10	0.003
Baseline liver fat proportion	38	4.6	3.3, 6.0	< 0.001
Baseline total testosterone (nmol/L)	38	-0.03	-0.09, 0.03	0.3
Baseline free testosterone (nmol/L)	38	0.00	0.00, 0.00	0.5
Baseline visceral fat (g)	38	0.00	0.00, 0.00	0.4
Follow up total testosterone (nmol/L)	37	-0.05	-0.09, -0.02	0.006
Follow up free testosterone (nmol/L)	37	0.00	0.00, 0.00	0.005
Follow up visceral fat (g)	38	0.00	0.00, 0.00	0.2

¹One participant did not have follow-up testosterone concentration. BMI: Body mass index.